Thalassemia and hypercoagulability

Ali T. Taher, Zaher K. Otrock, Imad Uthman, Maria D. Cappellini

Research output: Contribution to journalArticlepeer-review


Thalassemia is a congenital hemolytic disease caused by defective globin synthesis resulting in decreased quantity of globin chains. Although the life expectancy of β-thalassemia patients has markedly improved over the last few years, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in β-thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients. In this paper, we review the molecular and cellular mechanisms leading to hypercoagulability in β-thalassemia, with a special focus on thalassemia intermedia being the group with the highest incidence of thrombotic events as compared to other types of thalassemias. We also discuss the recommendations for thrombosis prophylaxis in these patients.

Original languageEnglish
Pages (from-to)283-292
Number of pages10
JournalBlood Reviews
Issue number5
Publication statusPublished - Sept 2008


  • Hypercoagulable state
  • Thalassemia
  • Thrombosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Thalassemia and hypercoagulability'. Together they form a unique fingerprint.

Cite this